WO1996021036A3 - Nucleic acid condensing agents with reduced immunogenicity - Google Patents

Nucleic acid condensing agents with reduced immunogenicity Download PDF

Info

Publication number
WO1996021036A3
WO1996021036A3 PCT/US1995/017005 US9517005W WO9621036A3 WO 1996021036 A3 WO1996021036 A3 WO 1996021036A3 US 9517005 W US9517005 W US 9517005W WO 9621036 A3 WO9621036 A3 WO 9621036A3
Authority
WO
WIPO (PCT)
Prior art keywords
condensing agents
immunogenicity
amino acid
nucleic acid
reduced immunogenicity
Prior art date
Application number
PCT/US1995/017005
Other languages
French (fr)
Other versions
WO1996021036A2 (en
Inventor
Polo Nicholas J De
David Chi-Tang Hsu
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to AU46905/96A priority Critical patent/AU4690596A/en
Publication of WO1996021036A2 publication Critical patent/WO1996021036A2/en
Publication of WO1996021036A3 publication Critical patent/WO1996021036A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Abstract

Nucleic acid condensing agents with reduced immunogenicity are generated either by conjugation of polycations or by selection of basic amino acid regions from proteins. Conjugation involves a chemical linkage between a polyalkylene glycol, such as polyethylene glycol, or a polysaccharide, such as dextran, and a polycation. Additionally, gene delivery vehicles, such as viral vectors, may be conjugated with polyalkylene glycol or polysaccharide, to reduce their immunogenicity. Basic amino acid regions of proteins are identified by isoelectric point, and amino acid composition. These condensing agents are complexed with nucleic acids and used to deliver genes to cells. Immunogenicity is assessed by whether neutralizing antibody is induced and by whether a serum component inactivates the complexes.
PCT/US1995/017005 1994-12-30 1995-12-26 Nucleic acid condensing agents with reduced immunogenicity WO1996021036A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46905/96A AU4690596A (en) 1994-12-30 1995-12-26 Nucleic acid condensing agents with reduced immunogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36678794A 1994-12-30 1994-12-30
US08/366,787 1994-12-30

Publications (2)

Publication Number Publication Date
WO1996021036A2 WO1996021036A2 (en) 1996-07-11
WO1996021036A3 true WO1996021036A3 (en) 1996-09-06

Family

ID=23444497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/017005 WO1996021036A2 (en) 1994-12-30 1995-12-26 Nucleic acid condensing agents with reduced immunogenicity

Country Status (2)

Country Link
AU (1) AU4690596A (en)
WO (1) WO1996021036A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7001764B2 (en) * 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
EP0819758B1 (en) * 1996-07-16 2006-09-20 Archibald James Mixson Cationic vehicle: DNA complexes and their use in gene therapy
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
DE19649645A1 (en) * 1996-11-29 1998-06-04 Hoechst Ag Multiple functional ligand system for target cell-specific transfer of nucleotide sequences
EP1905837A1 (en) * 1997-03-03 2008-04-02 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US6569426B2 (en) 1997-04-03 2003-05-27 Genzyme Corporation Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
CA2285416A1 (en) * 1997-04-03 1998-10-08 Genzyme Corporation Polymer-modified viruses
PL337033A1 (en) 1997-05-21 2000-07-31 Univ Leland Stanford Junior Composition for and methods of enhancing transport through permeable biological membranes
DE19726186A1 (en) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
WO1999000145A1 (en) * 1997-06-26 1999-01-07 Albany Medical College Antigenic modulation of viral particules
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
EP0963758A3 (en) * 1998-05-07 2000-03-22 Universiteit Gent Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
ATE411049T1 (en) * 1998-05-20 2008-10-15 Expression Genetics Inc LACTOSE OR GALACTOSE-POLYETHYLENE GLYCOL-GRABTED POLY-L-LYSINE AS A GENE CARRIER
WO2000011202A1 (en) * 1998-08-24 2000-03-02 Genzyme Corporation Cationic complexes of polymer-modified adenovirus
PL348513A1 (en) * 1998-12-03 2002-06-03 Aventis Pharma Sa Novel nucleic acid transferring agents, compositions containing them and uses
FR2786700B1 (en) * 1998-12-03 2002-12-06 Aventis Pharma Sa NOVEL NUCLEIC ACID TRANSFERS, COMPOSITIONS CONTAINING THEM, AND USES THEREOF
EP1063254A1 (en) * 1999-06-25 2000-12-27 Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung Copolymers for the transport of nucleic acids in the cell
EP1198489B1 (en) * 1999-06-25 2004-04-28 Christian Plank Combinations for introducing nucleic acids into cells
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
JP2003507438A (en) 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド Enhanced delivery of drugs across and into epithelial tissue using oligoarginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
DE10015906B4 (en) * 2000-03-30 2006-09-07 Ibfb Pharma Gmbh Directed gene transfer into Thy-1 positive cells
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
DE102014016901B4 (en) 2014-09-17 2021-08-12 Friedrich-Schiller-Universität Jena Process for the production of new dextran derivatives as active ingredient carrier systems and their use
US10814299B2 (en) 2015-11-18 2020-10-27 Pacific Biosciences Of California, Inc. Loading nucleic acids onto substrates
WO2018118992A1 (en) 2016-12-19 2018-06-28 Quantum-Si Incorporated Loading molecules into sample wells for analysis
WO2018204810A1 (en) 2017-05-05 2018-11-08 Quantum-Si Incorporated Substrates having modified surface reactivity and antifouling properties in biological reactions
WO2019136202A2 (en) 2018-01-08 2019-07-11 Quantum-Si Incorporated System and methods for electrokinetic loading of sub-scale reaction chambers
KR20220079943A (en) 2019-10-11 2022-06-14 퀀텀-에스아이 인코포레이티드 Surface modification in vapor phase

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2122325A2 (en) * 1971-01-20 1972-09-01 Maes Roland Polynucleic acid/polycationic compounds - for potentiating antiviral vaccines
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
EP0388758A1 (en) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Protein-polycation conjugate
WO1992005250A1 (en) * 1990-09-25 1992-04-02 University Of Connecticut Prolonging expression of polynucleotides introduced into a cell
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
WO1992020316A2 (en) * 1991-05-14 1992-11-26 University Of Connecticut Targeted delivery of genes encoding immunogenic proteins
WO1993004701A1 (en) * 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
WO1994023050A1 (en) * 1993-04-05 1994-10-13 University Of Connecticut Targeted delivery of genes encoding antisense polyribonucleotides
WO1995033061A1 (en) * 1994-05-31 1995-12-07 Boehringer Ingelheim International Gmbh Method for introducing nucleic acid in higher eukaryotic cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2122325A2 (en) * 1971-01-20 1972-09-01 Maes Roland Polynucleic acid/polycationic compounds - for potentiating antiviral vaccines
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0388758A1 (en) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Protein-polycation conjugate
WO1992005250A1 (en) * 1990-09-25 1992-04-02 University Of Connecticut Prolonging expression of polynucleotides introduced into a cell
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
WO1992020316A2 (en) * 1991-05-14 1992-11-26 University Of Connecticut Targeted delivery of genes encoding immunogenic proteins
WO1993004701A1 (en) * 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
WO1994023050A1 (en) * 1993-04-05 1994-10-13 University Of Connecticut Targeted delivery of genes encoding antisense polyribonucleotides
WO1995033061A1 (en) * 1994-05-31 1995-12-07 Boehringer Ingelheim International Gmbh Method for introducing nucleic acid in higher eukaryotic cells

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BACHRACH, HOWARD L.: "Ribonucleic acid of foot-and-mouth disease virus;an ultrasensitive plaque assay", PROC. SOC. EXP. BIOL. MED. (1966), 123(3), 939-45 CODEN: PSEBAA, December 1966 (1966-12-01), XP000569883 *
D.T. CURIEL ET AL.: "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery", PROC. NATL. ACAD. SCI. USA, vol. 88, October 1991 (1991-10-01), pages 8850 - 8854, XP000569906 *
E. WAGNER ET AL.: "DNA-binding transferrin conjugates as functional gene-delivery agents: synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety", BIOCONJUGATE CHEM., vol. 2, no. 4, 1991, pages 226 - 231, XP002002761 *
E. WAGNER ET AL.: "Transferrin-polycation conjugates as carriers for DNA uptake into cells", PROC. NATL. ACAD. SCI. USA, vol. 87, May 1990 (1990-05-01), pages 3410 - 3414, XP002002759 *
E. WAGNER ET AL.: "Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells", PROC. NATL. ACAD. SCI. USA, vol. 88, May 1991 (1991-05-01), pages 4255 - 4259, XP002002758 *
HAVLIZA, D. ET AL: "Complex formation between poliovirus RNA and polycations", ARCH. BIOCHEM. BIOPHYS. (1971), 147(1), 85-98 CODEN: ABBIA4, 1971, XP000569881 *
HULL, R.: "Effect of DEAE- dextran on the nucleic acids of two plant viruses", J. GEN. VIROL. (1971), 11(PT. 2), 111-17 CODEN: JGVIAY, 1971, XP000569879 *
K. ARNOLD ET AL.: "The dielectric properties of aqueous solutions of pol{ethylene glycol} and their influence on membrane structure", BIOCHEMICA ET BIOPHYSICA ACTA, vol. 815, 1985, pages 515 - 518, XP002002762 *
M. LAVITRANO ET AL.: "The interaction between exogenous DNA and sperm cells", MOL. REPROD. DEV., vol. 31, no. 3, 1992, pages 161 - 169, XP000569627 *
M. ZENKE ET AL.: "Receptor-mediated endocytosis of transferrin-polycation conjugates: An efficient way to introduce DNA into hematopoietic cells", PROC. NATL. ACAD. SCI. USA, vol. 87, May 1990 (1990-05-01), pages 3655 - 3659, XP002002760 *
MAES R F ET AL: "POTENTIATION OF FOOT-AND-MOUTH DISEASE VACCINES WITH POLY CATIONIC NUCLEIC - ACID COMPLEXES.", ARCH VIROL 55 (4). 1977 (RECD 1978) 275-286. CODEN: ARVIDF ISSN: 0304-8608, XP002002764 *
T.P KOGAN: "The synthesis of substituted methoxy-poly{ethyleneglycol} derivatives suitable for selective protein modification", SYNTHETIC COMMUNICATIONS, vol. 22, no. 16, 1992, pages 2417 - 2424, XP002002763 *
WARDEN, DAVID ET AL: "Influence of diethylaminoethyl- dextran on uptake and degradation of polyoma virus deoxyribonucleic acid by mouse embryo cells", J. VIROL. (1969), 4(4), 380-7 CODEN: JOVIAM, 1969, XP000569882 *
WENTZKY, P. ET AL: "Influence of polycations on the interaction between poliovirus multistranded ribonucleic acid and HeLa cells", J. VIROL. (1971), 8(1), 35-40 CODEN: JOVIAM, 1971, XP000569880 *

Also Published As

Publication number Publication date
AU4690596A (en) 1996-07-24
WO1996021036A2 (en) 1996-07-11

Similar Documents

Publication Publication Date Title
WO1996021036A3 (en) Nucleic acid condensing agents with reduced immunogenicity
JPH06172201A (en) Biologically active protein composition
Nieto et al. Purification and quaternary structure of the hormonally induced protein uteroglobin
ATE237312T1 (en) NUCLEIC ACID COMPLEXES ENCAPSULATED IN LIPOSOMES
JP2000506865A (en) Targeted delivery of genes encoding interferons
WO2002000730A3 (en) Pd-l2 molecules: novel pd-1 ligands and uses therefor
AU9174398A (en) Peptides
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
EP1566445A3 (en) Viral core protein-cationic lipid-nucleic acid-delivery complexes
WO2000043043B1 (en) Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
CA2101332A1 (en) Antibody polycation conjugates
Dainiak et al. Affinity precipitation of monoclonal antibodies by nonstoichiometric polyelectrolyte complexes
JP2003503569A (en) Copolymer for transporting nucleic acids to cells
Déas et al. In vivo-targeted gene delivery using antibody-based nonviral vector
WO2000047611A3 (en) Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
WO2002026803A3 (en) 22108 and 47916, novel human thioredoxin family members and uses thereof
WO2024017379A1 (en) Preparation method for polyethylene glycol conjugate of active polypeptide or protein
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
Veronese Enzyme surface modification by polymers for improved delivery
Shin et al. Conjugation of succinylated gelatin to soybean trypsin inhibitor
WO2002034896A3 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
Sun Characterization of human glucose-6-phosphate isomerase of different sizes.
WO2002000863A3 (en) 32140, a novel human aldehyde dehydrogenase and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase